ALS Centre Tours

CHU Bretonneau

Care Missions:
* Consultation of recourse for MND
* Management of MND patients from diagnosis to last stages
* Quaterly Multidisciplinary follow-up of MND patients
* Coordonation of  medical, paramedical and social support at home in collaboration with the NeuroCentre Network

logo tourss
CHU Bretonneau

Research:
Genetics
* Identification of susceptibility factors of ALS
* Setup of next generation sequencing

Metabolomics
* Identification of CSF and blood biomarkers for the diagnostic and the pronostic of ALS

Clinical Trials
* Contribution to clinical trials
* Development of pharmacogenomics

We are also developing scientific projects on Molecular Imaging focused on neuro-inflammation.

We are setting-up a ALS Registry in the Centre Val de Loire which is an extension of the Registry of the Limousin

Communications and Publications of the results of our studies during French and International ALS Meeting and into national and international reviews.

Contact
Location
CHU Bretonneau 2 Boulevard Tonnellé, 37044 Tours

Prinicipal investigators

Philippe Corcia

Professor of Neurology

Philippe Corcia is professor of Neurology at the ALS Centre of CHU Brettonneau, France

Philippe Corcia
Current trials
Recruiting
Phase iii

TUDCA-ALS (TUDCA)

Industry sponsored trial

TUDCA (tauroursodeoxycholic acid) is a small molecule that is being explored for its potential as a treatment for ALS

Read more
In preparation
Phase iii

PreLude (Lithium carbonate)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.

Read more
In preparation
Phase ii

Lighthouse (Triumeq)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of Triumeq, a therapy developed for treatment of HIV that has shown to slow progression in ALS

Read more
In preparation
Phase iii

iAdore (Oral edaravone)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of oral edaravone (TW001), a formulation that reduces oxidative stress

Read more